Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations

Haruyasu Murakami, Hiroshi Nokihara, Hidetoshi Hayashi, Takashi Seto, Keunchil Park, Koichi Azuma, Chun Ming Tsai, James Chih Hsin Yang, Makoto Nishio, Sang We Kim, Katsuyuki Kiura, Akira Inoue, Koji Takeda, Jin Hyoung Kang, Tomoki Nakagawa, Kentaro Takeda, Rio Akazawa, Yuichiro Kaneko, Masashi Shimazaki, Satoshi MoritaMasahiro Fukuoka, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR)-activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non-small-cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once-daily, oral, EGFR TKI that inhibits both activating and resistance mutations. This ASP8273 dose-escalation/dose-expansion study (NCT02192697) was undertaken in two phases. In phase I, Japanese patients (aged ≥20 years) with NSCLC previously treated with ≥1 EGFR TKI received escalating ASP8273 doses (25-600 mg) to assess safety/tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) by the Bayesian Continual Reassessment Method. In phase II, adult patients with T790M-positive NSCLC in Japan, Korea, and Taiwan received ASP8273 at RP2D to further assess safety/tolerability and determine antitumor activity, which was evaluated according to Simon's two-stage design (threshold response = 30%, expected response = 50%, α = 0.05, β = 0.1). Overall, 121 (n = 45 [33W/12M] phase I, n = 76 [48W/28M]) phase 2) patients received ≥1 dose of ASP8273. In phase I, RP2D and MTD were established as 300 and 400 mg, respectively. As 27 of the 63 patients treated with ASP8273 300 mg achieved a clinical response, ASP8273 was determined to have antitumor activity. The overall response rate at week 24 in all patients was 42% (n = 32/76; 95% confidence interval, 30.9-54.0). Median duration of progression-free survival was 8.1 months (95% confidence interval, 5.6, upper bound not reached). The most commonly reported treatment-related adverse event in phase II was diarrhea (57%, n = 43/76). ASP8273 300 mg was generally well tolerated and showed antitumor activity in Asian patients with both EGFR-activating and T790M mutations.

Original languageEnglish
Pages (from-to)2852-2862
Number of pages11
JournalCancer Science
Volume109
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Protein-Tyrosine Kinases
Maximum Tolerated Dose
Confidence Intervals
Safety
Korea
Taiwan
Disease-Free Survival
Diarrhea
Japan
Therapeutics

Keywords

  • clinical trial
  • epidermal growth factor receptor
  • non-small-cell carcinoma
  • signal transduction inhibitors/kinase inhibitor
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Murakami, H., Nokihara, H., Hayashi, H., Seto, T., Park, K., Azuma, K., ... Nakagawa, K. (2018). Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. Cancer Science, 109(9), 2852-2862. https://doi.org/10.1111/cas.13724

Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. / Murakami, Haruyasu; Nokihara, Hiroshi; Hayashi, Hidetoshi; Seto, Takashi; Park, Keunchil; Azuma, Koichi; Tsai, Chun Ming; Yang, James Chih Hsin; Nishio, Makoto; Kim, Sang We; Kiura, Katsuyuki; Inoue, Akira; Takeda, Koji; Kang, Jin Hyoung; Nakagawa, Tomoki; Takeda, Kentaro; Akazawa, Rio; Kaneko, Yuichiro; Shimazaki, Masashi; Morita, Satoshi; Fukuoka, Masahiro; Nakagawa, Kazuhiko.

In: Cancer Science, Vol. 109, No. 9, 01.09.2018, p. 2852-2862.

Research output: Contribution to journalArticle

Murakami, H, Nokihara, H, Hayashi, H, Seto, T, Park, K, Azuma, K, Tsai, CM, Yang, JCH, Nishio, M, Kim, SW, Kiura, K, Inoue, A, Takeda, K, Kang, JH, Nakagawa, T, Takeda, K, Akazawa, R, Kaneko, Y, Shimazaki, M, Morita, S, Fukuoka, M & Nakagawa, K 2018, 'Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations', Cancer Science, vol. 109, no. 9, pp. 2852-2862. https://doi.org/10.1111/cas.13724
Murakami, Haruyasu ; Nokihara, Hiroshi ; Hayashi, Hidetoshi ; Seto, Takashi ; Park, Keunchil ; Azuma, Koichi ; Tsai, Chun Ming ; Yang, James Chih Hsin ; Nishio, Makoto ; Kim, Sang We ; Kiura, Katsuyuki ; Inoue, Akira ; Takeda, Koji ; Kang, Jin Hyoung ; Nakagawa, Tomoki ; Takeda, Kentaro ; Akazawa, Rio ; Kaneko, Yuichiro ; Shimazaki, Masashi ; Morita, Satoshi ; Fukuoka, Masahiro ; Nakagawa, Kazuhiko. / Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. In: Cancer Science. 2018 ; Vol. 109, No. 9. pp. 2852-2862.
@article{c80978c8ea9441d8a64a3a29144f6d6b,
title = "Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations",
abstract = "Epidermal growth factor receptor (EGFR)-activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non-small-cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once-daily, oral, EGFR TKI that inhibits both activating and resistance mutations. This ASP8273 dose-escalation/dose-expansion study (NCT02192697) was undertaken in two phases. In phase I, Japanese patients (aged ≥20 years) with NSCLC previously treated with ≥1 EGFR TKI received escalating ASP8273 doses (25-600 mg) to assess safety/tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) by the Bayesian Continual Reassessment Method. In phase II, adult patients with T790M-positive NSCLC in Japan, Korea, and Taiwan received ASP8273 at RP2D to further assess safety/tolerability and determine antitumor activity, which was evaluated according to Simon's two-stage design (threshold response = 30{\%}, expected response = 50{\%}, α = 0.05, β = 0.1). Overall, 121 (n = 45 [33W/12M] phase I, n = 76 [48W/28M]) phase 2) patients received ≥1 dose of ASP8273. In phase I, RP2D and MTD were established as 300 and 400 mg, respectively. As 27 of the 63 patients treated with ASP8273 300 mg achieved a clinical response, ASP8273 was determined to have antitumor activity. The overall response rate at week 24 in all patients was 42{\%} (n = 32/76; 95{\%} confidence interval, 30.9-54.0). Median duration of progression-free survival was 8.1 months (95{\%} confidence interval, 5.6, upper bound not reached). The most commonly reported treatment-related adverse event in phase II was diarrhea (57{\%}, n = 43/76). ASP8273 300 mg was generally well tolerated and showed antitumor activity in Asian patients with both EGFR-activating and T790M mutations.",
keywords = "clinical trial, epidermal growth factor receptor, non-small-cell carcinoma, signal transduction inhibitors/kinase inhibitor, tyrosine kinase inhibitor",
author = "Haruyasu Murakami and Hiroshi Nokihara and Hidetoshi Hayashi and Takashi Seto and Keunchil Park and Koichi Azuma and Tsai, {Chun Ming} and Yang, {James Chih Hsin} and Makoto Nishio and Kim, {Sang We} and Katsuyuki Kiura and Akira Inoue and Koji Takeda and Kang, {Jin Hyoung} and Tomoki Nakagawa and Kentaro Takeda and Rio Akazawa and Yuichiro Kaneko and Masashi Shimazaki and Satoshi Morita and Masahiro Fukuoka and Kazuhiko Nakagawa",
year = "2018",
month = "9",
day = "1",
doi = "10.1111/cas.13724",
language = "English",
volume = "109",
pages = "2852--2862",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations

AU - Murakami, Haruyasu

AU - Nokihara, Hiroshi

AU - Hayashi, Hidetoshi

AU - Seto, Takashi

AU - Park, Keunchil

AU - Azuma, Koichi

AU - Tsai, Chun Ming

AU - Yang, James Chih Hsin

AU - Nishio, Makoto

AU - Kim, Sang We

AU - Kiura, Katsuyuki

AU - Inoue, Akira

AU - Takeda, Koji

AU - Kang, Jin Hyoung

AU - Nakagawa, Tomoki

AU - Takeda, Kentaro

AU - Akazawa, Rio

AU - Kaneko, Yuichiro

AU - Shimazaki, Masashi

AU - Morita, Satoshi

AU - Fukuoka, Masahiro

AU - Nakagawa, Kazuhiko

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Epidermal growth factor receptor (EGFR)-activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non-small-cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once-daily, oral, EGFR TKI that inhibits both activating and resistance mutations. This ASP8273 dose-escalation/dose-expansion study (NCT02192697) was undertaken in two phases. In phase I, Japanese patients (aged ≥20 years) with NSCLC previously treated with ≥1 EGFR TKI received escalating ASP8273 doses (25-600 mg) to assess safety/tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) by the Bayesian Continual Reassessment Method. In phase II, adult patients with T790M-positive NSCLC in Japan, Korea, and Taiwan received ASP8273 at RP2D to further assess safety/tolerability and determine antitumor activity, which was evaluated according to Simon's two-stage design (threshold response = 30%, expected response = 50%, α = 0.05, β = 0.1). Overall, 121 (n = 45 [33W/12M] phase I, n = 76 [48W/28M]) phase 2) patients received ≥1 dose of ASP8273. In phase I, RP2D and MTD were established as 300 and 400 mg, respectively. As 27 of the 63 patients treated with ASP8273 300 mg achieved a clinical response, ASP8273 was determined to have antitumor activity. The overall response rate at week 24 in all patients was 42% (n = 32/76; 95% confidence interval, 30.9-54.0). Median duration of progression-free survival was 8.1 months (95% confidence interval, 5.6, upper bound not reached). The most commonly reported treatment-related adverse event in phase II was diarrhea (57%, n = 43/76). ASP8273 300 mg was generally well tolerated and showed antitumor activity in Asian patients with both EGFR-activating and T790M mutations.

AB - Epidermal growth factor receptor (EGFR)-activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non-small-cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once-daily, oral, EGFR TKI that inhibits both activating and resistance mutations. This ASP8273 dose-escalation/dose-expansion study (NCT02192697) was undertaken in two phases. In phase I, Japanese patients (aged ≥20 years) with NSCLC previously treated with ≥1 EGFR TKI received escalating ASP8273 doses (25-600 mg) to assess safety/tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) by the Bayesian Continual Reassessment Method. In phase II, adult patients with T790M-positive NSCLC in Japan, Korea, and Taiwan received ASP8273 at RP2D to further assess safety/tolerability and determine antitumor activity, which was evaluated according to Simon's two-stage design (threshold response = 30%, expected response = 50%, α = 0.05, β = 0.1). Overall, 121 (n = 45 [33W/12M] phase I, n = 76 [48W/28M]) phase 2) patients received ≥1 dose of ASP8273. In phase I, RP2D and MTD were established as 300 and 400 mg, respectively. As 27 of the 63 patients treated with ASP8273 300 mg achieved a clinical response, ASP8273 was determined to have antitumor activity. The overall response rate at week 24 in all patients was 42% (n = 32/76; 95% confidence interval, 30.9-54.0). Median duration of progression-free survival was 8.1 months (95% confidence interval, 5.6, upper bound not reached). The most commonly reported treatment-related adverse event in phase II was diarrhea (57%, n = 43/76). ASP8273 300 mg was generally well tolerated and showed antitumor activity in Asian patients with both EGFR-activating and T790M mutations.

KW - clinical trial

KW - epidermal growth factor receptor

KW - non-small-cell carcinoma

KW - signal transduction inhibitors/kinase inhibitor

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85052655193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052655193&partnerID=8YFLogxK

U2 - 10.1111/cas.13724

DO - 10.1111/cas.13724

M3 - Article

C2 - 29972716

AN - SCOPUS:85052655193

VL - 109

SP - 2852

EP - 2862

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 9

ER -